Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
VENLO, The Netherlands & REDWOOD CITY, Calif. - QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA), a global provider of Sample to Insight solutions, has expanded its bioinformatics presence with the opening of a new data center in Melbourne, Australia. This facility aims to bolster QIAGEN’s bioinformatics data infrastructure and support genomic testing labs in the Australia/Asia-Pacific region, including Australia, New Zealand, New Guinea, and surrounding islands.
The Melbourne data center is the latest addition to QIAGEN’s global network, which now includes eight data centers across various strategic locations. This expansion not only supports the growing data center market in the Australia/Asia-Pacific area but also ensures that local genomic testing laboratories can host sensitive data in compliance with Australian privacy and health data regulations.
Dominic John, Vice President of QIAGEN Digital Insights, stated, "With the opening of this data center, we are strengthening our ability to serve the Australian market and the broader Australia/Asia-Pacific region. This new facility will allow diagnostic labs to confidently deliver clinical next-generation sequencing testing services while meeting evolving data sovereignty laws."
The new facility underscores QIAGEN’s commitment to data security, compliance, and operational excellence. It provides tailored bioinformatics solutions that enable secure, efficient, and innovative clinical and diagnostic services.
QIAGEN has over 25 years of industry experience, with 90,000 users worldwide and 4 million profiled patient cases. The company continues to focus on delivering bioinformatics solutions that empower labs and researchers in the field of genomics and personalized medicine.
The information in this article is based on a press release statement from QIAGEN. For more details about QIAGEN Digital Insights and its global data infrastructure, interested parties can visit the company’s website.
QIAGEN N.V. is a Netherlands-based holding company specializing in extracting and gaining molecular insights from samples containing DNA, RNA, and proteins. The company serves more than 500,000 customers globally across Life Sciences and Molecular Diagnostics and employs over 5,700 people in over 35 locations worldwide. InvestingPro analysis reveals the company maintains excellent financial health with a current ratio of 3.61, indicating strong liquidity. The stock currently trades with relatively low volatility, making it an interesting option for stability-focused investors. For comprehensive financial analysis and additional insights, including 12 more exclusive ProTips, consider exploring InvestingPro’s detailed coverage.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.